The next wave of immunotherapy needs builders who are bold.

We're advancing a new class of therapy designed to redirect the pathogen-primed T-cell memory every adult already carries onto the cells that drive disease.

Our work sits at the intersection of immunology, recombinant protein engineering, and translational medicine. We're looking for scientists, clinicians, and operators who run toward hard problems instead of away from them.

We value rigor over hype. Concrete data over consensus. And people who care as much about the patient at the end of the pipeline as the molecule on the bench.

If that sounds like you, we'd love to meet you.